The U.S. Food and Drug Administration (FDA) has approved Libtayo® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

Existing Users Log In